Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core MSCI EAFE ETF (IEFA) vs Medpace Holdings Inc (MEDP) Price & Performance

iShares Core MSCI EAFE ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares Core MSCI EAFE ETF vs Medpace Holdings Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $101.02, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). Which is the better fit depends on your goals.

IEFAMEDP
Sector
Broad Market / FactorTechnology
52-Week High
$101.09$620.59
52-Week Low
$84.72$393.42
Market Cap
$16.90B
Enterprise Value
$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core MSCI EAFE ETF

IEFA, the iShares Core MSCI EAFE ETF, trades at $101.02, up 0.49% today, with a bullish technical signal driven by strong moving average alignment. The ETF focuses on developed international equities outside the U.S. and Canada, offering diversification and a dividend yield of 3.30% (The Motley Fool, 2026-06-17). Recent news highlights its cost efficiency and income appeal compared to peers like EFA and VXUS.

The outlook remains positive due to international diversification benefits and potential Fed rate cuts, but risks include currency fluctuations and geopolitical tensions. Analyst sentiment is favorable, emphasizing lower expense ratios and stable dividend income for long-term investors.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core MSCI EAFE ETF

IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.

Read more on IEFA

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP